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Abstract
Background: A pilot screening campaign in Rwanda, based on careHPV-testing followed by visual inspection with
acetic acid triage (careHPV+VIA triage), was evaluated against other WHO-recommended screening options, namely
HPV screen-and-treat and VIA screen-and-treat.
Methods: 764 women aged 30-69 underwent at visit 1: i) VIA, and cervical cell collection for ii) careHPV in Rwanda,
and iii) liquid-based cytology and GP5+/6+ HR-HPV PCR in The Netherlands. All 177 women positive by VIA, careHPV
and/or PCR were recalled, of whom 84% attended. At visit 2, VIA was again used to triage screen-positive
women for treatment and to obtain biopsies from all women either from visible lesions or at 12 o’clock of the
squamocolumnar junction. Cross-sectional screening indices were estimated primarily against histological high-grade
squamous intraepithelial lesions or worse (hHSIL+), after imputation of missing histology data, based on 1-visit or 2-visit
approaches.
Results: In a 1-visit screen-and-treat approach, VIA had sensitivity and specificity of 41% and 96%, respectively, versus 71%
and 88% for careHPV, and 88% and 86% for PCR. In a 2-visit approach (in which hHSIL+ imputed among women without
visit 2 were considered untreated) careHPV sensitivity dropped to 59% due to loss of 13% of hHSIL+. For careHPV+VIA
triage, sensitivity dropped further to 35%, as another 24% of hHSIL+ were triaged to no treatment.
Conclusions: CareHPV was not as sensitive as gold-standard PCR, but detected considerably more hHSIL+ than VIA.
However, due to careHPV-positive hHSIL+ women being lost to follow-up and/or triaged to no treatment, 2-visit careHPV
+VIA triage did not perform better than VIA screen-and-treat.
Keywords: Human papillomavirus, Visual inspection, Cervical cancer, Screening, Rwanda
Background
Cervical cancer is the most commonly occurring female
cancer in Rwanda, with a high incidence rate typical of
many sub-Saharan African countries (42 cases per 100,000
women per year [1]). In response to this burden, Rwanda
embarked upon a national plan for cervical cancer screen-
ing [2] and, in 2011, was the first African country to initiate
a national vaccination program against human papillomavi-
rus (HPV) [2, 3], the necessary cause of cervical cancer [4].
In order to also reduce cervical cancer among older
cohorts of women unprotected by the vaccination pro-
gram, in 2013, the Rwandan Ministry of Health (MoH)
initiated a screening campaign. This campaign was based
on primary careHPV testing and the use of visual
inspection with acetic acid (VIA) to triage careHPV-
positive women for treatment [2]. Indeed, WHO guide-
lines for cervical screening in low and middle income
countries (LMIC) include an algorithm of high-risk (HR)
HPV-testing followed by VIA triage as one of its three
recommended screen-and-treat options [5]. Although
some experiences have since been reported [6–8], WHO
recommendations acknowledged that there was no
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evidence on the effectiveness of VIA triage among
women known to be HR HPV-positive. The prediction
of the efficacy of a HPV + VIA triage approach, as well
as its recommendation over a VIA screen-and-treat ap-
proach, came from combining evidence of separate per-
formances of HPV and VIA [5].
We nested an evaluation of the 2013 Rwandan MoH
screening campaign within the framework of a population-
based HPV survey performed in collaboration between the
Rwandan MoH and the International Agency for Research
on Cancer (IARC) to jointly monitor the impact of HPV
vaccination [9] and cervical screening. The careHPV-
testing followed by VIA triage algorithm was principally
evaluated against the gold standard of high-grade squa-
mous intraepithelial lesions or worse (HSIL+) as detected
by histology, and was compared with the other two WHO
recommended screen-and-treat options for LMICs, namely
HPV screen-and-treat and VIA screen-and-treat.
Methods
Population
Between July 2013 and May 2014, during a population-
based survey of HPV prevalence, 2508 women aged 18-
69 years were invited and underwent collection of
cervical cells in Muhima hospital or eight other health
centers in Nyarugenge district, Kigali, Rwanda. Study
procedures have been described in detail elsewhere [9].
In short, exfoliated cervical cells were obtained from all
women using a cytobrush (Rovers Medical Devices, The
Netherlands), and were placed in PreservCyt medium
(Cytyc-Hologic, Marlborough, MA, USA) for the per-
formance of liquid-based cytology and HPV detection
using GP5+/6+−based polymerase chain reaction (PCR)
at VU University Medical Center, Amsterdam (see below),
the results of which have already been published [9].
Participants aged ≥ 30 years (or ≥ 25 years if known to
be HIV-positive) (n = 1062) were also offered visual in-
spection at their first study visit. The cervix was visually
inspected after application of dilute acetic acid, with re-
sults reported according to the IARC criteria [10]. This
test is hereafter referred to as “screening VIA” (to differ-
entiate it from VIA triage that was used at a second visit
to decide treatment, see below). Furthermore, for a sub-
set of these women for whom their study visit coincided
with the implementation of the 2013 Rwandan MoH pilot
careHPV screening campaign in the same hospital [2], a
second cervical cell sample was collected with a careBrush
and placed in a vial containing collection medium for
careHPV testing. A total of 764 women with results for
careHPV are the subject of the present report (Fig. 1).
The study had the approval of both the Research Eth-
ical Board of the Rwanda Ministry of Health and the
IARC Ethics Committee. Written informed consent was
obtained from all study participants.
CareHPV
Samples were tested using the careHPV platform (Qia-
gen Corporation, Gaithersburg, MD, USA) installed in
Muhima Hospital, according to the manufacturer’s
instructions. The careHPV test is a validated signal-
amplification, rapid batch diagnostic test for the detec-
tion of DNA of 13 HR-HPV types (HPV16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68) and HPV66. CareHPV
results were communicated as soon as possible to the
screening clinic to arrange the follow-up of careHPV-
positive women. However, due to the practical logistics,
careHPV results were not available on the same day as
the initial visit.
Liquid-based cytology
Slides for liquid-based cytology were prepared from cell
samples in PreservCyt medium using a Thin Prep 3000
processor (Cytyc-Hologic), stained according to manu-
facturer’s instructions and read at the Department of
Pathology at the VU University Medical Center,
Amsterdam, the Netherlands. Cytological diagnosis was
made according to CISOE-A standards and was trans-
lated into the Bethesda 2001 terminology system [11].
HPV testing by PCR
DNA was extracted from the PreservCyt sample using
magnetic beads on a robotic system at the Department
of Pathology at the VU University Medical Center,
Amsterdam. β-globin PCR analysis was conducted to
confirm the presence of human DNA in all specimens
[12] and GP5+/6+−mediated PCR was used to amplify
HPV DNA [13]. HPV positivity was assessed by
hybridization of PCR products in an enzyme immuno-
assay with two oligoprobe cocktails that, together, detect
44 HPV types. HPV genotyping was subsequently con-
ducted by reverse-line blot (RLB) hybridization of PCR
products as described previously [14]. HR-HPV refers to
13 high-risk HPV types only (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59 and 68) [4]. Non-high-risk HPV types
are ignored in the current analysis.
Cervical disease assessment
One hundred and seventy seven women who were posi-
tive by screening VIA and/or by careHPV and/or for
HR-HPV infection by PCR (for which results became
available at a later date) were all recalled for a second
visit, among whom 148 (84%) attended and 29 (16%)
were lost to follow-up (Fig. 1). Six of 587 women nega-
tive for the three screening tests were also inadvertently
recalled for a second visit.
At the second visit, VIA was again used to triage
women for immediate treatment (by cryotherapy, ther-
mocoagulation, or if ineligible, loop electrosurgical exci-
sion procedures) or not, according to the protocol of the
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Rwandan MoH careHPV screening campaign [2], here-
after referred to as “VIA triage”. In addition, for research
purposes only, biopsies were to be taken from all women
undergoing VIA triage, either VIA-directed to a visible
lesion, or, in the absence of a visible lesion, randomly
from 12 o’clock of the squamocolumnar junction, prior
to any treatment. Histological confirmation of biopsies
was performed at the Department of Pathology at the
University Teaching Hospital of Kigali, and all biopsies
from women with histological and/or cytological abnor-
malities were re-read by a specialist (TMD) reported
according to LAST criteria [15] which became the refer-
ence diagnosis. Adequate histology results were obtained
from 139 (90%) of 154 women who underwent VIA
triage at the second visit, among whom 12 cases were
diagnosed as hHSIL+ (including 1 invasive squamous
cell carcinoma).
Statistical analysis
Conventional screening indices of cross-sectional accur-
acy, including sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), and their
95% confidence intervals, were calculated primarily
against histological HSIL or worse (hHSIL+). Corrected
indices were calculated after imputation of missing hist-
ology data. In the corrected model, pseudo-observations
were created for women without a valid histology result,
weighted by the probability of hHSIL+ among women
with valid histology outcomes and the same combination
of cytology, VIA, careHPV and PCR results [16–18].
Hence, in addition to the 12 confirmed hHSIL+, an add-
itional 5 hHSIL+ were estimated among women without
a valid histology outcome (Table 1). Only corrected indi-
ces are shown, but crude indices assuming that all
women without valid histology had no hHSIL+ can also
be calculated from the data described in Table 1. As sec-
ondary analyses, screening indices were also calculated
against the outcome of cytological HSIL or worse
(cHSIL+), or against a composite outcome of cytological
and/or histological HSIL+ (composite HSIL+).
The performance of VIA, careHPV and PCR were
first compared in a hypothetical scenario of single-
visit screen-and-treat, treating all test-positive women
at the same visit. In this model, the HSIL+ cases
Fig. 1 Flow chart of study population, procedures and outcomes, Rwanda 2013-14
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(imputed hHSIL+ and/or observed cHSIL+) among the 29
women without a second visit are assumed to be treated.
Secondly, based on the actual 2-visit approach that was
used, we compared the Rwandan MoH careHPV screen-
ing campaign algorithm of careHPV primary testing at the
first visit followed by VIA triage to decide treatment or
not, against the counterfactual option of treating all
careHPV-positive women at the second visit. In this ana-
lysis, the HSIL+ cases among the women without a sec-
ond visit are lost to follow-up and remain untreated.
Results
Of the 764 screened women, mean age was 43 years
[interquartile range = 35-49 years], 84% were literate,
66% were currently married, 56% reported more than
one lifetime sexual partner, 35% were known to be HIV-
positive, and only 2.6% reported previous attendance to
cervical screening (Additional file 1: Table S1).
Table 2 shows indices of cross-sectional accuracy by dif-
ferent primary screening methods, firstly in a 1-visit
screen-and-treat scenario. Positivity rate was 5.1% for VIA
screen-and-treat, 13.4% for careHPV and 15.7% for PCR.
CareHPV showed higher sensitivity against hHSIL+ (71%)
than VIA (41%), but lower than that of PCR (88%). NPV
was also higher for careHPV (99.2%) than screening VIA
(98.6%) but lower than that of PCR (99.7%). Specificity of
careHPV (89%), on the other hand, was lower than for
screening VIA (95%), and similar to PCR (87%). PPV for
hHSIL+ was highest for screening VIA (17%).
Table 2 also shows screening indices of cross-sectional
accuracy based on a 2-visit approach, i.e., HPV primary
screening followed by referral of all HPV-positive women
for treatment, in which 29 women were lost to follow-up
and would not be treated even if screen-positive. Treating
all careHPV positive women in a 2-visit approach resulted
in the treatment of 11.6% of women and was associated
with a sensitivity of 59% against hHSIL+. Using VIA to tri-
age careHPV-positives at the second visit resulted in the
treatment of only 2.9% of women, but was associated with
a drop in sensitivity to 35%.
A similar drop in sensitivity was observed for using
VIA to triage PCR-positives in a 2-visit approach, from
73% for treatment of all PCR-positives, down to 47%. Of
note, PCR also provided information on HPV genotype:
8 of the 11 PCR-positive hHSIL+ observed at the second
visit were HPV16/18-positive (6 HPV16, 2 HPV18), of
which 5 (62%) were VIA triaged to no treatment.
Relative performances of the different testing approaches
were consistent when using cytological HSIL+ (cHSIL+)
(Additional file 1: Table S2), or a composite cytological/histo-
logical HSIL+ endpoint (Additional file 1: Table S3), instead
of hHSIL+. Furthermore, relative performances against
hHSIL+ were also consistent in sensitivity analyses restricted
to women aged 25-44 years only (Additional file 1: Table S4).
Discussion
This evaluation of the performance of the 2013 Rwandan
MoH cervical cancer screening campaign is the first
Table 1 hHSIL+ among 764 women with and without biopsies respectively, by combination of cytology, VIA, PCR and careHPV
results
Cytology1 VIA2 PCR3 careHPV N Women with biopsy Women without biopsy All women
N Confirmed N Estimated hHSIL+ %
hHSIL+ hHSIL+
<cHSIL – – – 587 6 0 581 0.0 0.0 0.0
– – + 28 20 1 8 0.4 1.4 5.0
– + – 42 28 1 14 0.5 1.5 3.6
– + + 51 41 2 10 0.5 2.5 4.9
+ – – 27 24 0 3 0.0 0.0 0.0
+ – + 2 1 0 1 0.0 0.0 0.0
+ + – 3 2 1 1 0.5 1.5 50.0
+ + + 4 3 2 1 0.7 2.7 66.7
cHSIL+ – + – 3 2 2 1 } 1.3 } 4.3 }25.0
– + + 14 10 1 4
+ + + 3 2 2 1 1.0 3.0 100.0
764 139 12 625 5 17 2.2
1 19 missing cytology are considered cytology negative
2 Screening VIA at first visit
3 HR-HPV positivity for GP5+/6+-based PCR testing
cHSIL cytological high-grade squamous intraepithelial lesions, hHSIL histological high-grade squamous intraepithelial lesions, HR-HPV high-risk human papillomavirus,
PCR polymerase chain reaction, VIA visual inspection with acetic acid
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real-world comparison of the three options endorsed by
the 2013 WHO guidelines for screening and treatment
of precancerous cervical lesions in LMICs. Although
careHPV did not perform quite as well as a reference
PCR HPV test, a careHPV screen-and-treat approach
would have treated more hHSIL+ than VIA screen-and-
treat (albeit with a higher treatment rate overall). In the
actual 2-visit approach used in Rwanda, necessitated by
the inability for rapid turnaround of careHPV results, an
unacceptably high proportion of women with HPV-
positive hHSIL+ were subsequently lost to follow-up
and/or triaged by VIA to no treatment, with a result that
the 2-visit approach of careHPV+VIA triage ended up
performing similarly to VIA screen-and-treat.
In a 1-visit screen-and-treat approach, sensitivity of
careHPV was substantially greater than that of VIA, as
shown previously [19]. The 71% estimate of careHPV
sensitivity represents that at the beginning of experience
with the test platform in Rwanda, and was lower than
that reported in previous large evaluations (84-100%)
[20–24]. It was also lower than that of a HR-HPV PCR
test (GP5+/6+) that was done on the same samples in a
reference laboratory. Of note, careHPV was performed
on clinician-collected samples in the current study, but
has been shown to be similarly applicable to self-
collected samples [21, 23, 25–27].
Although the initial plan of the Rwandan MoH was to
deliver careHPV results on the same day [2] a 1-visit
careHPV screen-and-treat approach proved unfeasible.
This was partly due to the time requirement of collec-
tion of 90 samples coupled with a 3.5 h testing run, but
was also hampered by a high number of invalid runs that
required re-testing, which are technical features that are
not expected to be shared by all HPV tests. Thus,
careHPV-positive women were called back for triage and
treatment in a second visit, which was associated with
the loss to follow-up of an estimated 13% of careHPV-
positive hHSIL+. Of note, the loss to follow-up in our
well-supported research program is likely to be lower
than in the wider Rwanda MoH campaign, and can be
compared to 25-30% in other experiences of recalling
HPV-positive women [6–8, 28].
The fact that not all careHPV-positive women were
treated at the second visit but only those positive by a
second VIA triage test, greatly reduced the number of
women receiving treatment in Rwanda, from 13% to 3%.
However, an important fraction (4 out of 10) careHPV-
positive hHSIL+ seen at visit 2 were also triaged to no
treatment, so that hHSIL+ sensitivity for careHPV+VIA
triage dropped to 35%. These findings confirm those of
similar studies in which a HPV + VIA triage algorithm
was associated with sensitivity of only 33% for cervical
intraepithelial neoplasia (CIN)2+ in Cameroon [7] and
34% for cHSIL+ in Papua New Guinea [29]. In other set-
tings, the proportion of HPV-positive CIN2+ triaged to
no treatment have been reported as 75% [6], 34% [8] or,
estimated in the presence of verification bias due to lack
of systematic biopsies, 18% [30].
Histologically confirmed HSIL is a more accurate diag-
nosis of true cervical precancerous lesions than cyto-
logical HSIL, and was considered as the gold standard
outcome for screening indicators in our analysis. How-
ever, histology can also suffer from verification bias
when biopsies are not obtained from all screened
women. In the present study, we attempted to address
this problem by obtaining histology from a high propor-
tion of screen-positive women, by expert review of all
biopsies according to recommended criteria [15], and by




hHSIL+ treated Sensitivity (95%-CI) Specificity (95%-CI) PPV (95%-CI) NPV (95%-CI)
Screening approach N % N
1-visit1
Screen-and-treat VIA 39 5.1 7 41 (18 - 67) 96 (94 - 97) 18 (8 - 34) 98.6 (97.5 – 99.3)
Screen-and-treat CareHPV 102 13.4 12 71 (44 - 90) 88 (85 - 90) 12 (6 - 20) 99.2 (98.2 – 99.8)
Screen-and-treat PCR 120 15.7 15 88 (64 - 99) 86 (83 - 88) 13 (7 - 20) 99.7 (98.9 - 100)
2-visit2
Treatment based on careHPV 89 11.6 10 59 (33 - 82) 89 (87 - 92) 11 (6 - 20) 99.0 (97.9 – 99.6)
Treatment based on careHPV+VIA triage3 22 2.9 6 35 (14 - 62) 98 (97 - 99) 27 (11 - 50) 98.5 (97.4 – 99.3)
Treatment based on PCR 100 13.1 13 77 (50 - 93) 88 (86 - 91) 13 (7 - 21) 99.4 (98.5 – 99.8)
Treatment based on PCR + VIA triage 20 2.6 7 41 (18 - 67) 98 (97 - 99) 35 (15 - 59) 98.7 (97.5 – 99.4)
1 3 hHSIL+ imputed among 29 women without a second visit are considered treated
2 3 hHSIL+ imputed among 29 women without a second visit are considered untreated
3 Treatment based on careHPV and VIA triage was the screening approach used, according to Rwanda MoH screening recommendation [2]
CI confidence interval, hHSIL histological high-grade squamous intraepithelial lesions, MoH Ministry of Health, NPV negative predictive value, PCR polymerase chain
reaction, PPV positive predictive value, VIA visual inspection with acetic acid
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imputing underlying hHSIL+ among the few from whom
we did not have biopsies. It is gold-standard to obtain
biopsies directed by colposcopy, but in the present
study, as in other similar evaluations [7], they were di-
rected by VIA. Nevertheless, we were able to show that
screening accuracy indices were consistent when evalu-
ated against the outcome of cHSIL+ detected on liquid-
based cytology samples that were collected from all
women at the same visit as those for careHPV, and eval-
uated in The Netherlands blindly to HPV results.
We report on VIA as applied in a low-resource setting
during the implementation of a government screening
program, which is more likely to reflect real world con-
ditions than those estimated from clinical trials, as VIA
is subjective and known to vary in quality according to
level of training of personnel. In addition to their
previous local training, study health workers were none-
theless provided a refresher course on VIA and thermo-
coagulation prior to the start of the study. Despite this,
the estimate of primary VIA screening sensitivity (41%)
fell into the lower range of earlier estimates from similar
studies [31], but comparable to that in other large real
world experiences that also included widespread training
and quality control [32, 33].
Our evaluation was associated with a number of weak-
nesses, most notably the small number of cases of
hHSIL+, which affected the stability of estimates and
prohibited the possibility of performing sub-analyses.
For example, a substantial subset (35%) of our study
population was HIV-positive. This should not explain
the poor sensitivity of VIA, as positivity rate and sensi-
tivity tends to be higher in HIV-positive persons for
HPV and VIA alike [34]. Furthermore, our semi-
observational study design prohibited the evaluation of
whether VIA triage of careHPV positives in a 1-visit ap-
proach may have treated a few extra hHSIL+ that were
subsequently lost to follow-up. Lastly, performance of
the HPV + VIA triage algorithm might have improved if
careHPV-positive VIA-negative women had been re-
screened for persistent HPV-positivity at one year, ac-
cording to the initial plan of the pilot screening cam-
paign [2]. We were not able to assess this algorithm as,
following the first round of screening, the Rwanda MoH
decided not to continue with careHPV-testing.
Conclusions
In summary, our data send a warning against the real-
world utility of a 2-visit approach to VIA-triage of HPV-
positive women as an algorithm for cervical cancer
screening [6–8, 29]. Indeed, it appears that investment
in HPV-testing to identify women at highest risk of
hHSIL+ needs to be coupled with systematic treatment
(where possible, in a single visit), to obtain the long term
prevention of CIN2+ observed for HPV screen-and-treat
approaches in prevention trials [35]. In this pragmatic
“HPV screen-and-treat” approach, which has been put
into practice in large implementation studies [25], VIA is
still used, not to determine whether to treat or not, but
to determine eligibility for cryotherapy/thermocoagula-
tion. Although this approach will treat some women
without disease, it will also destroy cells from the cer-
vical squamocolumnar junction where most HPV-
related neoplastic lesions originate [36]. Indeed, in a
modelling exercise, even with re-screening at one year of
HPV-positives, 2-visit VIA-triage of HPV positive
women was not a cost effective approach in comparison
to treating all HPV-positive women [37].
In the experience in Rwanda, the losses associated with
requirement of a second visit and/or with VIA triage led
to a 2-visit approach of careHPV+VIA triage treating a
similar number of hHSIL (6 out of 17) as VIA screen-and-
treat. Indeed, independently of the current analysis, the
Rwanda MoH has decided, for pragmatic reasons, to
resort to a recommendation of VIA screen-and-treat for
cervical cancer screening for the time being.
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